Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse Events.

[1]  Sally Morton,et al.  The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration , 2019, Annals of Internal Medicine.

[2]  Sally Morton,et al.  The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement , 2019, Annals of Internal Medicine.

[3]  M. Hoshen,et al.  Translating clinical trial results into personalized recommendations by considering multiple outcomes and subjective views , 2019, npj Digital Medicine.

[4]  A. Ng,et al.  Clinical Value of Predicting Individual Treatment Effects for Intensive Blood Pressure Therapy: A Machine Learning Experiment to Estimate Treatment Effects from Randomized Trial Data , 2019, Circulation. Cardiovascular quality and outcomes.

[5]  James H. Faghmous,et al.  Assessment of Risk of Harm Associated With Intensive Blood Pressure Management Among Patients With Hypertension Who Smoke , 2019, JAMA network open.

[6]  J. Williamson,et al.  Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial , 2019, JAMA.

[7]  Leif E. Peterson,et al.  Impact of Cardiovascular Risk on the Relative Benefit and Harm of Intensive Treatment of Hypertension. , 2018, Journal of the American College of Cardiology.

[8]  Patrick Rossignol,et al.  Individualizing treatment choices in the systolic blood pressure intervention trial , 2018, Journal of hypertension.

[9]  Ewout W Steyerberg,et al.  The proposed 'concordance-statistic for benefit' provided a useful metric when modeling heterogeneous treatment effects. , 2018, Journal of clinical epidemiology.

[10]  Daniel W. Jones,et al.  Potential US Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline , 2018, Circulation.

[11]  Trevor Hastie,et al.  Some methods for heterogeneous treatment effect estimation in high dimensions , 2017, Statistics in medicine.

[12]  Anna C. Porter,et al.  Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT). , 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  Sanjay Basu,et al.  Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials , 2017, PLoS medicine.

[14]  James R. Powell,et al.  Cost‐Effectiveness of Intensive versus Standard Blood‐Pressure Control , 2017 .

[15]  J. Spertus,et al.  Personalizing the Intensity of Blood Pressure Control: Modeling the Heterogeneity of Risks and Benefits From SPRINT (Systolic Blood Pressure Intervention Trial) , 2017, Circulation. Cardiovascular quality and outcomes.

[16]  Issa J Dahabreh,et al.  Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient-centred evidence. , 2016, International journal of epidemiology.

[17]  Редакционная Статья.  СРАВНЕНИЕ ЭФФЕКТИВНОСТИ ИНТЕНСИВНОГО И СТАНДАРТНОГО РЕЖИМА ПРИМЕНЕНИЯ АНТИГИПЕРТЕНЗИВНОЙ ТЕРАПИИ: РЕЗУЛЬТАТЫ РАНДОМИЗИРОВАННОГО ИССЛЕДОВАНИЯ SPRINT (SYSTOLIC BLOOD PRESSURE INTERVENTION TRIAL) , 2016 .

[18]  C. Escobar Cervantes,et al.  [A randomized trial of intensive versus standard blood pressure control]. , 2016, Semergen.

[19]  Jackson T. Wright,et al.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.

[20]  Olga V. Demler,et al.  Tests of calibration and goodness‐of‐fit in the survival setting , 2015, Statistics in medicine.

[21]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[22]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[23]  Walter T Ambrosius,et al.  The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT) , 2014, Clinical trials.

[24]  M. Pencina,et al.  On the C‐statistics for evaluating overall adequacy of risk prediction procedures with censored survival data , 2011, Statistics in medicine.

[25]  H. Zou,et al.  Regularization and variable selection via the elastic net , 2005 .

[26]  Sara T Brookes,et al.  Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. , 2004, Journal of clinical epidemiology.

[27]  Ralph B. D'Agostino,et al.  Evaluation of the Performance of Survival Analysis Models: Discrimination and Calibration Measures , 2003, Advances in Survival Analysis.

[28]  T. Peters,et al.  Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. , 2001, Health technology assessment.